insulin glargine + lixisenatide

Insulin glargine + lixisenatide is a fixed-dose combination drug used to treat adults with type 2 diabetes mellitus who are inadequately controlled on basal insulin or a glucagon-like peptide-1 (GLP-1) receptor agonist alone. Insulin glargine is a long-acting basal insulin analog that lowers blood glucose by facilitating cellular uptake of glucose and suppressing hepatic glucose production. Lixisenatide is a GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, inhibits glucagon release, slows gastric emptying, and increases satiety. The combination provides complementary effects on fasting plasma glucose (FPG) and postprandial plasma glucose (PPG), resulting in improved glycemic control compared to either component alone[1][5][6]. It is administered as a once-daily subcutaneous injection[8]. The product was developed by Sanofi and approved for use in the United States in 2016 and the European Union in 2017[5].

Brand names

SoliquaSuliquaSoliqua 100/33

Other names

insulin glargine/lixisenatide